Aptevo raises about $3.0M as warrant holders exercise at reduced $1.08 price in inducement deal
Aptevo Therapeutics, a clinical-stage immuno-oncology company, agreed with existing warrant holders on November 12, 2026 to have them exercise 2,777,778 warrants for cash at a reduced $1.08 per share, generating roughly $3.0 million in gross proceeds. In return, holders will receive new unregistered inducement warrants for up to 13,888,890 shares at $1.08, exercisable after stockholder approval and expiring five years after first exercise. Roth Capital Partners advised on the deal, and Aptevo has agreed to file a resale registration statement with the SEC.
Company's press release (SEC filing): Aptevo Therapeutics Inc. ↗
Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.
IndustryCompany releaseIM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
IndustryCompany releaseHelus Pharma, formerly Cybin, reports $150.9M six-month net loss as share compensation rises
IndustryCompany releaseIM Cannabis sells German arm to CEO-controlled Slil, refocusing on Israel
IndustryCompany releaseDataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
IndustryCompany releaseXenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient
IndustryCompany release